



2nd AME Italian Meeting
 Associazione Medici Endocrinologi
Joint Meeting with AACE
 American Association of Clinical Endocrinologists
 Reggio Emilia, Italy - November 8-10, 2002



Clinical Symposia
Methodological Issues


Chairman
 Antonino Cartabellotta (Palermo, Italy)


© GIMBE®



- ### Levels of evidence
- 1** High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias
 - 1* Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
 - 1· Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
 - 2** High quality systematic reviews of case control or cohort studies
High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
 - 2* Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
 - 2· Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
 - 3 Non-analytic studies, e.g. case reports, case series
 - 4 Expert opinion
- SIGN 50. August 2002
- © GIMBE®

- ### Grades of recommendations
- A** At least one meta-analysis, systematic review of RCTs, or RCT rated as 1** and directly applicable to the target population; or
A body of evidence consisting principally of studies rated as 1*, directly applicable to the target population, and demonstrating overall consistency of results
 - B** A body of evidence including studies rated as 2**, directly applicable to the target population, and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 1** or 1*
 - C** A body of evidence including studies rated as 2*, directly applicable to the target population and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 2**
 - D** Evidence level 3 or 4; or
Extrapolated evidence from studies rated as 2*
- SIGN 50. August 2002
- © GIMBE®





1. Searching: pre-appraised sources

Practice Guidelines →

- National Guideline Clearinghouse
- CMA Infobase
- SIGN
- Guidelines finder (UK)
- Other databases of PG
- MEDLINE

Evidence-compendia →

- *Clinical Evidence* (issue 7, August 2002)

Systematic reviews →

- *Cochrane Library* (issue 4, 2002)
- MEDLINE

© GIMBE®

1. Searching: primary studies

Randomized Controlled Trials
Observational studies →

- MEDLINE
- *Best-Evidence 5*

© GIMBE®

2. Critical Appraisal

Users' Guide to Biomedical Literature
JAMA 1993-2000

AGREE Instrument
(Final version, September 2001)
www.agreecollaboration.org

© GIMBE®

Clinical Symposia Format

• Presentation of clinical scenario and relevant questions	10'
• Remote control vote	5'
• Evidence-based data presentation	15'
• Comments of experts on topic-answers provided by the audience and on grey zones and clinical applicability of evidence	15'
• Open discussion and final remarks	15'

© GIMBE®

The Electronic Library is free available at:

www.gimbe.org/eventi/ame_ace

© GIMBE®